Ulocuplumab - Bristol-Myers Squibb
Alternative Names: BMS-936564; MDX-1338Latest Information Update: 14 May 2024
At a glance
- Originator Medarex
- Developer Bristol-Myers Squibb; Medarex; University of Bari
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Solid tumours; Waldenstrom's macroglobulinaemia
- No development reported B-cell lymphoma; B-cell prolymphocytic leukaemia; Multiple myeloma; Neuroectodermal tumours; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 31 Dec 2022 Bristol-Myers Squibb and Dana-Farber Cancer Institute terminates phase I/II trials in Waldenstrom's macroglobulinaemia (Combination therapy) in USA due to sponsor decision to end follow-up early (IV) (NCT03225716)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Neuroectodermal-tumours in Italy
- 28 Jan 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)